LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Home・Aandelen Lijst・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Gesloten

4.3 2.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.29

Max

4.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -7.7M
Verkoop	-10M 529K
EPS	-0.056
Winstmarge	-1,463.516
Werknemers	44
EBITDA	-10M -7.7M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-6.7M 873M
Vorige openingsprijs	1.43
Vorige sluitingsprijs	4.3

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

3.255 / 3.365 Steun & Weerstand

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 nov 2025, 10:30 UTC

Winsten

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 nov 2025, 10:30 UTC

Acquisities, Fusies, Overnames

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 22:42 UTC

Marktinformatie

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

21 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 21:47 UTC

Marktinformatie

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 nov 2025, 21:43 UTC

Marktinformatie

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 nov 2025, 20:18 UTC

Marktinformatie

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 nov 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 nov 2025, 19:48 UTC

Marktinformatie

Precious Metals Fall for the Week -- Market Talk

21 nov 2025, 19:44 UTC

Winsten

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 nov 2025, 19:37 UTC

Marktinformatie

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

21 nov 2025, 19:27 UTC

Marktinformatie

Winsten

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 nov 2025, 19:20 UTC

Marktinformatie

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 nov 2025, 18:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 nov 2025, 18:37 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 nov 2025, 18:34 UTC

Marktinformatie

Winsten

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 nov 2025, 18:28 UTC

Winsten

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 18:03 UTC

Marktinformatie

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Global Equities Roundup: Market Talk

21 nov 2025, 17:24 UTC

Marktinformatie

Intuit Seen on Path to Increase Growth -- Market Talk

21 nov 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 nov 2025, 17:05 UTC

Marktinformatie

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 nov 2025, 16:56 UTC

Marktinformatie

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 nov 2025, 16:47 UTC

Marktinformatie

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 nov 2025, 16:35 UTC

Acquisities, Fusies, Overnames

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 nov 2025, 16:09 UTC

Winsten

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 nov 2025, 15:59 UTC

Marktinformatie

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Arbutus Biopharma Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.